蒙脱石散联合消旋卡多曲颗粒治疗小儿病毒性肠炎的疗效分析

目的 探讨蒙脱石散联合消旋卡多曲颗粒治疗小儿病毒性肠炎的疗效。 方法 选择自2015年1月-2016年1月绍兴市人民医院儿科收治的105例病毒性肠炎患儿,按照治疗方法的不同,将患儿分为3组,A组、B组和C组,每组35例。3组患儿给予基础治疗,同时A组患儿给予蒙脱石散,按照年龄阶段给予相应的剂量;B组患儿给予消旋卡多曲颗粒,剂量按照每次按每公斤体重服用1.5 mg;C组患儿给予蒙脱石散联合消旋卡多曲颗粒,剂量与A、B组相同。对比3组的临床疗效和不良反应。 结果 C组总有效率达100%,高于A组的88.57%和B组的85.71%,差异有统计学意义(χ2=5.10,P<0.01)。C组患儿的止吐时间、退热时间、大便性状恢复时间、大便次数恢复正常时间显著短于其他2组,差异有统计学意义(P<0.01)。经过治疗3组患儿血清中天门冬氨转氨酶(AST)、肌酸转氨酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)水平显著低于治疗前,差异有统计学意义(P<0.01)。3组下降幅度比较,C组患儿治疗后AST、CK、CK-MB、LDH水平显著低于A组和B组,差异有统计学意义(P<0.05)。治疗期间未发现严重不良反应。 结论 蒙脱石散联合消旋卡多曲颗粒治疗小儿病毒性肠炎疗效优于2种药物单独用药,未发现不良反应,值得临床推广。 

Curative effect of montmorillonite powder combined with racecadotril granules on viral enteritis in children

Objective To investigate the curative effect of montmorillonite powder combined with racecadotril granules on viral enteritis in children. Methods A total of 105 children with viral enteritis in Shaoxing People's Hospital from January,2015 to January,2016 were collected and divided into group A,B and C with 35 people in each group.The three groups of children were given relevant treatment,while group A received montmorillonite powder providing appropriate dose according to the age;group B received racecadotril granules,taking each dose of the drug per kilogram in accordance with 1.5 mg body weight;group C received montmorillonite powder and racecadotril granules,the dose was the same as that of group A and group B.The clinical efficacy and adverse reactions were compared between the three groups. Results The total effective rate in group C was 100.00%,which was significantly higher than that of group A and group B,88.57% and 85.71%,respectively and the difference had statistical difference (χ2=5.10,P<0.01),The antiemetic time,fever clearance time,recovery time of defecation traits back to normal,recovery time of defecation frequency back to normal were shorter than those in the other two groups,with a statistical difference (P<0.01).After treatment,the levels of AST、CK、CK-MB、LDH in three groups were significantly lower than those before the treatment (P<0.01).Between the 3 groups,the decline of AST,CK,CK-MB,LDH in group C was more significant than those in the other two groups,and the difference was significant (P<0.05).No severe adverse reactions were found during the treatment. Conclusion Montmorillonite powder combined with racecadotril is better than the other single medication groups and found no adverse reactions,which is worthy of clinical promotion.